Too often, drug developers think conversations with the FDA start when they file their application
This week's Fierce LifeSci is brought to you by Catalent. Trouble viewing? Click here.
|
| Monday, September 20, 2021 | 11am ET / 8am PT | |
|
|
| A growing number of drug launches have faltered at the final hour because manufacturing processes weren’t up to FDA standards. Some went through that disappointment more than once. How can drug developers properly monitor quality throughout the clinical production process and fix any issues that arise—before the FDA brings out the red flags? In this webinar, we’ll look at the diverse set of tactics companies can use to forestall manufacturing disappointments, from recruitment to partnerships to regulatory communication and more. |
---|
| |
|
|
| You are currently subscribed as newsletter@newslettercollector.com If you no longer wish to receive promotions from Fierce LifeSciences, simply unsubscribe. Refer to our Privacy Policy. Fierce LifeSciences is a division of Questex LLC. 685 3rd Ave 21st Floor New York, NY 10017 © 2021 Questex LLC. All Rights Reserved. Reproduction in whole or in part is prohibited without written permission. | |
|
|